EUVIMEDEUVIMED entdecken
Open Access

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer

Sakthivel Muniyan, Raghupathy Vengoji, Rama Krishna Nimmakayala, Parthasarathy Seshacharyulu, Balaji Perumalsamy, Zahraa Wajih Alsafwani, Sham S Kakar, Lynette M Smith, Nicole Shonka, Benjamin A Teply, Subodh M Lele, Moorthy P Ponnusamy und 1 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Sakthivel Muniyan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: s.muniyan@unmc.ed…. Hauptthemen laut MEDLINE: Docetaxel, Drug Resistance, Neoplasm, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Nebraska Medical Center Fred & Pamela Buffett Cancer Center, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced prostate cancer (PCa) remains a significant clinical challenge, and docetaxel plays a significant role in disease management. Despite the efficacy of docetaxel as a first-line chemotherapy, resistance often develops. We developed three clinically relevant in vitro PCa cell models and transcriptomic analysis identified that the Paf1/RNA polymerase II complex component (PAF1)-associated pluripotent-transcription factor (TF), SOX2, plays a crucial role in docetaxel resistance. The cancer stem cell (CSC) transcriptional master regulator PAF1 is significantly higher in PCa cell lines, tumor tissues, and docetaxel resistant (DR) PCa cells than in age-matched control cells. To determine the molecular underlying and functional characteristics of PAF1 in resistance mechanisms, we performed coimmunoprecipitation, embryonic stem cell network proteins, in vitro tumor-initiating ability, and 3D multicellular organoid growth using PAF1 knockdown cells. Tet-inducible PAF1 depletion reduced the drug-efflux phenotype, tumor-initiating frequencies, and three-dimensional organoid growth of the docetaxel-resistant PCa cell lines. Functional studies also showed restoration of docetaxel sensitivity in a 3D tumorsphere model upon PAF1 depletion. PAF1 depletion was also associated with decreased pluripotent TFs and other CSC markers. This study provides a novel regulatory mechanism of docetaxel resistance in PCa through PAF1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelDrug Resistance, NeoplasmProstatic NeoplasmsHumansMaleCell Line, TumorGene Expression Regulation, NeoplasticNeoplastic Stem CellsTranscription FactorsSOXB1 Transcription FactorsAntineoplastic AgentsNuclear ProteinsOrganoidsAnimals

Stichwörter der Autor:innen

CRPCCancer stem-like cellsMulticellular organoid growthPAF1Therapy resistance

Substanzen

DocetaxelPAF1 protein, humanSOX2 protein, humanTranscription FactorsSOXB1 Transcription FactorsAntineoplastic AgentsNuclear Proteins

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: s.muniyan@unmc.edu.
  • Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
  • Department of Physiology, University of Louisville School of Medicine, Louisville, KY, 40202, USA.
  • Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
  • Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center…
  • Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Alli…

Förderung

  • NCI NIH HHS
  • University of Nebraska Medical Center Fred & Pamela Buffett Cancer Center
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Muniyan, S., Vengoji, R., Nimmakayala, R. K., Seshacharyulu, P., Perumalsamy, B., Alsafwani, Z. W., Kakar, S. S., Smith, L. M., Shonka, N., Teply, B. A., Lele, S. M., Ponnusamy, M. P., & Batra, S. K. (2025). PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217355

Vancouver

Muniyan S, Vengoji R, Nimmakayala RK, Seshacharyulu P, Perumalsamy B, Alsafwani ZW, et al. PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217355

BibTeX
@article{Muniyan2025,
  author = {Muniyan, Sakthivel and Vengoji, Raghupathy and Nimmakayala, Rama Krishna and Seshacharyulu, Parthasarathy and Perumalsamy, Balaji and Alsafwani, Zahraa Wajih and Kakar, Sham S and Smith, Lynette M and Shonka, Nicole and Teply, Benjamin A and Lele, Subodh M and Ponnusamy, Moorthy P and Batra, Surinder K},
  title = {PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217355}
}
Kostenlos starten →